-
1.发明申请HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS 审中-公开用作mTOR抑制剂的HEXAHYDROOXAZINOPTERINE化合物
公开(公告)号：WO2011025889A1
公开(公告)日：2011-03-03
申请号：PCT/US2010/046839
申请日：2010-08-26
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED , JIN, Bohan , SCORAH, Nicholas , DONG, Qing
Inventor： JIN, Bohan , SCORAH, Nicholas , DONG, Qing
IPC: C07D498/14 , A61K31/5383
CPC classification number: C07D498/14
Abstract: The present invention provides mTOR inhibitors of the formula wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods of making the compounds and intermediates thereof; and methods of using the compounds.
Abstract translation: 本发明提供下式的mTOR抑制剂，其中变量如本文所定义。 还提供了包含这些化合物的药物组合物，试剂盒和制品; 制备化合物及其中间体的方法; 和使用该化合物的方法。
-
公开(公告)号：WO2008079814A2
公开(公告)日：2008-07-03
申请号：PCT/US2007/087913
申请日：2007-12-18
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED , DONG, Qing , GONG, Xianchang , KALDOR, Stephen W. , KANOUNI, Toufike , SCORAH, Nicholas , WALLACE, Michael B. , ZHOU, Feng
Inventor： DONG, Qing , GONG, Xianchang , KALDOR, Stephen W. , KANOUNI, Toufike , SCORAH, Nicholas , WALLACE, Michael B. , ZHOU, Feng
IPC: C07D471/04 , A61K31/4375 , A61P35/00
CPC classification number: C07D471/04
Abstract: Compounds of the following formula are provided for use with MEK (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
Abstract translation: 提供下式的化合物用于MEK（I）：其中变量如本文所定义。 还提供了包含这些化合物的药物组合物，试剂盒和制品; 用于制备化合物的方法和中间体; 以及使用所述化合物的方法。
-
公开(公告)号：WO2021193983A2
公开(公告)日：2021-09-30
申请号：PCT/JP2021/014422
申请日：2021-03-25
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Abstract: The present disclosure provides GIP receptor agonist peptide compounds suitable for once per week dosing (QW), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by any of the formulas (I)-(V) or a salt thereof, and a medicament comprising the same are provided.
-
公开(公告)号：WO2014164558A1
公开(公告)日：2014-10-09
申请号：PCT/US2014/022801
申请日：2014-03-10
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED , LAWSON, John David , SABAT, Mark , SCORAH, Nicholas , SMITH, Christopher , VU, Phong H. , WANG, Haxia
Inventor： LAWSON, John David , SABAT, Mark , SCORAH, Nicholas , SMITH, Christopher , VU, Phong H.
IPC: C07D401/14 , C07D401/04 , C07D403/14 , A61K31/4725 , A61P35/00
CPC classification number: A61K31/4725 , A61K31/4375 , A61K31/4439 , A61K31/519 , C07D401/04 , C07D401/14 , C07D403/14 , C07D471/04
Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , and R 4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
Abstract translation: 公开了式1的化合物或其药学上可接受的盐，其中R 1，R 2，R 3和R 4在说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗I型超敏反应，自身免疫疾病，炎症性疾病，癌症，非恶性增殖性疾病和其它病症的用途 与BTK相关。
-
公开(公告)号：WO2012148548A1
公开(公告)日：2012-11-01
申请号：PCT/US2012/026589
申请日：2012-02-24
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED , CHANG, Edcon , GIBSON, Tony , JIN, Bohan , SCORAH, Nicholas , DONG, Qing
Inventor： CHANG, Edcon , GIBSON, Tony , JIN, Bohan , SCORAH, Nicholas , DONG, Qing
IPC: C07D498/14 , A61P29/00 , A61K31/5383
CPC classification number: C07D498/14 , A61K31/5383 , A61K45/06
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein Ar, R 1 , R 2 , R 3 , G 1 , G 2 , and m are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating inflammatory disorders, cardiovascular disease, cancer, and other conditions associated with ΡI3Κδ.
Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中Ar，R 1，R 2，R 3，G 1，G 2和m在说明书中定义。 本公开还涉及制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗炎症性疾病，心血管疾病，癌症以及与其相关的其它病症的用途。
-
Patent Agency Ranking
公开(公告)号：WO2009129401A8
公开(公告)日：2009-10-22
申请号：PCT/US2009/040832
申请日：2009-04-16
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED , BROWN, Jason, W. , DONG, Qing , GANGLOFF, Anthony, R. , PARASELLI, Bheema, R. , STAFFORD, Jeffrey, A. , SCORAH, Nicholas , SALSBURY, Jonathon, S. , DAS, Sanjib
Inventor： BROWN, Jason, W. , DONG, Qing , GANGLOFF, Anthony, R. , PARASELLI, Bheema, R. , STAFFORD, Jeffrey, A. , SCORAH, Nicholas , SALSBURY, Jonathon, S. , DAS, Sanjib
IPC: A61K31/437 , C07D471/04 , A61P25/00 , A61P35/00
Abstract: Compounds are provided for use with kinases that comprise a compound selected from the group consisting of formula (I): wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
-
公开(公告)号：WO2021193984A2
公开(公告)日：2021-09-30
申请号：PCT/JP2021/014423
申请日：2021-03-25
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
IPC: C07K14/605 , A61K38/00 , A61P1/08 , C12N15/00
Abstract: The present disclosure provides GIP receptor agonist peptide compounds suitable for once per day dosing (QD), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by any of the formulas (I)-(V) or a salt thereof, and a medicament comprising the same are provided.
-
公开(公告)号：WO2015134171A1
公开(公告)日：2015-09-11
申请号：PCT/US2015/015651
申请日：2015-02-12
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED , KEUNG, Walter , KWOK, Lily , SABAT, Mark , SCORAH, Nicholas , WANG, Haixia , WOODHEAD, Steven, John , GANGLOFF, Anthony, R.
Inventor： KEUNG, Walter , KWOK, Lily , SABAT, Mark , SCORAH, Nicholas , WANG, Haixia , WOODHEAD, Steven, John , GANGLOFF, Anthony, R.
IPC: C07D471/04 , C07D487/04 , A61K31/437 , A61K31/4985 , A61P29/00 , A61P37/00
CPC classification number: C07D487/04 , C07D471/04
Abstract: The present invention provides compounds of formula 1: which are useful as inhibitors of TBK-1, pharmaceutical compositions thereof, methods for treatment of conditions associated with TBK1, processes for making the compounds and intermediates thereof.
Abstract translation: 本发明提供式1化合物：其可用作TBK-1的抑制剂，其药物组合物，用于治疗与TBK1相关的病症的方法，用于制备化合物的方法及其中间体。
-
公开(公告)号：WO2009064675A1
公开(公告)日：2009-05-22
申请号：PCT/US2008/082846
申请日：2008-11-07
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED , ADAMS, Mark E. , DONG, Qing , KALDOR, Stephen W. , KANOUNI, Toufike , SCORAH, Nicholas , WALLACE, Michael B.
Inventor： ADAMS, Mark E. , DONG, Qing , KALDOR, Stephen W. , KANOUNI, Toufike , SCORAH, Nicholas , WALLACE, Michael B.
IPC: C07D471/04 , C07D498/04 , C07D513/04 , A61K31/4353 , A61P35/00
CPC classification number: C07D471/04 , C07D498/04 , C07D513/04
Abstract: Compounds of the following Formula (I) are provided for use with MEK: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
Abstract translation: 提供下式（I）的化合物与MEK一起使用：其中变量如本文所定义。 还提供了包含这些化合物的药物组合物，试剂盒和制品; 用于制备化合物的方法和中间体; 以及使用所述化合物的方法。
-
公开(公告)号：EP2678342B1
公开(公告)日：2015-01-07
申请号：EP12716773.2
申请日：2012-02-24
Applicant: Takeda Pharmaceutical Company Limited
Inventor： CHANG, Edcon , GIBSON, Tony , JIN, Bohan , SCORAH, Nicholas , DONG, Qing
IPC: C07D498/14 , A61P29/00 , A61K31/5383
CPC classification number: C07D498/14 , A61K31/5383 , A61K45/06
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.03 seconds)
